Pfizer Faces Valuation Discount Despite International Exposure

about 2 months ago

David Harrell

"Pfizer, even though it increased its U.S. revenue exposure, is still generating about 40% of its revenue outside of the United States and is trading at a sizeable discount of around 34% to its fair value estimate."

Pfizer is presented as undervalued with a 34% discount, despite having 40% international revenue. This may indicate a buying opportunity for investors comfortable with international revenue exposure within a largely U.S.-dominated portfolio.